Krilogy Financial LLC Purchases 3,650 Shares of Exact Sciences Corporation (EXAS)

Krilogy Financial LLC increased its position in Exact Sciences Corporation (NASDAQ:EXAS) by 1,460.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,900 shares of the medical research company’s stock after purchasing an additional 3,650 shares during the period. Krilogy Financial LLC’s holdings in Exact Sciences Corporation were worth $138,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fortaleza Asset Management Inc. bought a new position in shares of Exact Sciences Corporation in the 2nd quarter worth $106,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Exact Sciences Corporation by 17.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares in the last quarter. Financial Architects Inc lifted its holdings in shares of Exact Sciences Corporation by 90.0% in the 2nd quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after purchasing an additional 2,035 shares in the last quarter. Johnson Financial Group Inc. lifted its holdings in shares of Exact Sciences Corporation by 25.9% in the 2nd quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Exact Sciences Corporation by 66.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock worth $179,000 after purchasing an additional 2,013 shares in the last quarter. Institutional investors own 85.22% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Krilogy Financial LLC Purchases 3,650 Shares of Exact Sciences Corporation (EXAS)” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/10/13/krilogy-financial-llc-purchases-3650-shares-of-exact-sciences-corporation-exas.html.

In related news, SVP D Scott Coward sold 29,115 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now owns 64,991 shares in the company, valued at $3,064,975.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Graham Peter Lidgard sold 81,025 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $3,821,139.00. Following the sale, the insider now owns 366,519 shares of the company’s stock, valued at approximately $17,285,036.04. The disclosure for this sale can be found here. In the last quarter, insiders have sold 237,444 shares of company stock valued at $10,412,421. 4.00% of the stock is owned by company insiders.

A number of equities research analysts recently commented on the company. Craig Hallum increased their price target on Exact Sciences Corporation from $35.00 to $41.00 in a research report on Friday, July 7th. Benchmark Co. set a $50.00 price target on Exact Sciences Corporation and gave the company a “buy” rating in a research report on Friday, July 7th. Canaccord Genuity reissued a “buy” rating and issued a $42.00 price target (up from $38.00) on shares of Exact Sciences Corporation in a research report on Thursday, July 20th. BTIG Research reissued a “buy” rating and issued a $45.00 price target (up from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Finally, BidaskClub raised Exact Sciences Corporation from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Exact Sciences Corporation has a consensus rating of “Buy” and a consensus price target of $43.71.

Shares of Exact Sciences Corporation (NASDAQ EXAS) traded down 1.4487% during midday trading on Friday, hitting $47.3736. The stock had a trading volume of 1,282,988 shares. The stock’s market cap is $5.64 billion. The stock’s 50-day moving average is $44.43 and its 200-day moving average is $35.94. Exact Sciences Corporation has a 12 month low of $13.05 and a 12 month high of $50.65.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. The firm had revenue of $57.65 million for the quarter, compared to the consensus estimate of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. Equities analysts anticipate that Exact Sciences Corporation will post ($1.18) EPS for the current year.

Exact Sciences Corporation Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply